Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
King of Prussia, Pennsylvania--(Newsfile Corp. - November 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS), held in San Diego, California, from November 5-8, 2026."The growing body...